Cardiovascular Research Advance Access first published online on July 9, 2008
This version [Corrected Proof] published online on July 22, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn181
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Control of cardiac excitability by microRNAs
1 Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
2 Cardiovascular Research Institute, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
3 Research Center, Montreal Heart Institute, 5000 Belanger East, Montreal, Canada PQ H1T 1C8
4 Department of Medicine, University of Montreal, Montreal, Canada PQ H3C 3J7
* Corresponding authors. Tel: +86 451 8667 9473 (B.Y.) or Tel: +1 514 376 3330; Fax: +1 514 376 4452 (Z.W.) E-mail address: yangbf{at}ems.hrbmu.edu.cn (B.Y.) or wz.email{at}gmail.com (Z.W.)
Cardiovascular disease is the leading cause of morbidity and mortality in developed countries. The pathological process of the heart is associated with an altered expression profile of genes that are important for cardiac function. MicroRNAs (miRNAs) have recently emerged as one of the central players of gene expression regulation. The implications of miRNAs in the pathological process of the cardiovascular system have recently been recognized, and research on miRNAs in relation to cardiovascular disease has now become a most rapidly evolving field. In this review, we focus on miRNAs and control of cardiac excitability, aiming to provide a comprehensive overview on the available experimental data on regulation of cardiac conduction, repolarization, and automaticity by miRNAs. Aberrant expression of miRNAs in the diseased state of the heart and their arrhythmogenic or anti-arrhythmic potential will be discussed. Finally, the innovative miRNA-interference technologies developed lately for manipulating the action of miRNAs by interfering with their expression, stability, and function as new approaches for miRNA research and gene therapy will be introduced.
KEYWORDS miRNA; Arrhythmias; Cardiac excitability; Ion channels; Gene expression
Time for primary review: 25 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Goette Nicotine, atrial fibrosis, and atrial fibrillation: do microRNAs help to clear the smoke? Cardiovasc Res, August 1, 2009; 83(3): 421 - 422. [Full Text] [PDF]
|
|
|
|
|
|
Y. Lu, Y. Zhang, H. Shan, Z. Pan, X. Li, B. Li, C. Xu, B. Zhang, F. Zhang, D. Dong, et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection Cardiovasc Res, July 31, 2009; (2009) cvp232v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qin, B. Zhao, Y. Shi, C. Yao, L. Jin, and Y. Jin BMPRII is a direct target of miR-21 Acta Biochim Biophys Sin, July 1, 2009; 41(7): 618 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Condorelli and S. Dimmeler MicroRNAs: components of an integrated system controlling cardiac development, physiology, and disease pathogenesis Cardiovasc Res, September 1, 2008; 79(4): 551 - 552. [Full Text] [PDF]
|
|